Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates (original) (raw)
Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models
Angélique Boedec
Molecular Pharmaceutics, 2015
View PDFchevron_right
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
nirnoy dan
Pharmaceuticals (Basel, Switzerland), 2018
View PDFchevron_right
A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin based ADCs
Jeffrey Lau, Mary Go
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
View PDFchevron_right
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Wai Lee T. Wong, Siao Tsai, William Mallet
Nature Biotechnology, 2008
View PDFchevron_right
Antibody-Drug Conjugates: The New Frontier of Chemotherapy
Gianluca Sala
International Journal of Molecular Sciences
View PDFchevron_right
Antibody–drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
Yelena Kovtun
Therapeutic Delivery, 2011
View PDFchevron_right
Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
Colette Quinn
Exploration of Targeted Anti-tumor Therapy, 2021
View PDFchevron_right
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Roger Zabinski
Clinical Cancer Research, 2004
View PDFchevron_right
THE NEW AGE SAVIOUR FOR COMBATING CANCER: ANTIBODY DRUG CONJUGATES.
IJAR Indexing
View PDFchevron_right
Emerging Role of Antibody Drug Conjugates (ADCs) in Therapeutics: An Appraisal
Tatini Debnath
2017
View PDFchevron_right
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu
Signal Transduction and Targeted Therapy, 2022
View PDFchevron_right
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Martha Anderson
Journal of Pharmacology and Experimental Therapeutics, 2009
View PDFchevron_right
Large Molecule Therapeutics DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for
Kristi Elkins
2016
View PDFchevron_right
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E– and Duocarmycin-Based Anti-PSMA Antibody–Drug Conjugates for Treatment of PSMA-Expressing Tumors
Giulio Fracasso
Journal of Nuclear Medicine
View PDFchevron_right
Advances in antibody-drug conjugates: A new era of targeted cancer therapy
sushil kashaw
Drug discovery today, 2017
View PDFchevron_right
Development of a Cytotoxic Antibody–Drug Conjugate Targeting Membrane Immunoglobulin E-Positive Cells
Gordana Wozniak-Knopp
International Journal of Molecular Sciences
View PDFchevron_right
Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy
Sanjeev Gangwar
Bioorganic & Medicinal Chemistry Letters, 2018
View PDFchevron_right
A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
Daniel Krowarsch
International Journal of Molecular Sciences
View PDFchevron_right
Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)
Reza Tavakkol
Breast Cancer, 2020
View PDFchevron_right
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
Maryam Quraishi
Nature Communications
View PDFchevron_right
Antibody drug conjugate ,historical and future overview
Sahar Hammam
Sohag Medical Journal
View PDFchevron_right
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates
Gina Popa
Journal of controlled release : official journal of the Controlled Release Society, 2017
View PDFchevron_right
Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry
Surinder Kaur
Analytical Biochemistry, 2011
View PDFchevron_right
Evaluation of hydrophobic‐interaction‐chromatography Resins for purification of antibody‐drug conjugates using a mimetic model with adjustable hydrophobicity
Egbert Müller
Journal of Separation Science
View PDFchevron_right
Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins
Andreas Plückthun
View PDFchevron_right
Antibody Drug Conjugates for Cancer Therapy
mubabol journal
Journal of Babol University of Medical Sciences, 2017
View PDFchevron_right
DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Randall Dere
Molecular Cancer Therapeutics, 2013
View PDFchevron_right
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Anna Wolska
Drug Safety, 2019
View PDFchevron_right
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
Ben Coumbe
Oncoimmunology, 2018
View PDFchevron_right
Antibody drug conjugates: Progress, pitfalls, and promises
Santosh Kesari
Human antibodies, 2018
View PDFchevron_right